FDA Advisory Panel Rejects Cangrelor for PCI

The antiplatelet drug cangrelor should not be approved for percutaneous coronary intervention (PCI) and interrupted antiplatelet therapy, according to the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee. After reviewing data from the CHAMPION PHOENIX trial during the daylong meeting, the panel voted 2-7 against using the drug for the prevention of thrombotic events associated with PCI and 0-9 against using the drug in surgical patients whose antiplatelet therapy is interrupted. The decision now heads to the FDA.

Clinical Topics: Invasive Cardiovascular Angiography and Intervention

Keywords: Adenosine Monophosphate, Advisory Committees, Purinergic P2Y Receptor Antagonists, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Thrombosis, United States Food and Drug Administration

< Back to Listings